Associated Papers
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
41346570 (PubMed )
Supplement: MCO2-6-e70483-s002.xlsx › Tumour_cellularity
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H et al.
Frontiers in Oncology, 2022
36072793 (PubMed )
Supplement: Table_3.xlsx › somatic_alterations
Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells.
Wan R et al.
Oncotargets and Therapy, 2021
DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.
Mäki-Nevala S et al.
Ebiomedicine, 2019
To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications.
Wrighton KH et al.
Cellular Signalling, 2008
Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation.
Yang L et al.
Human Mutation, 2006
TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability.
Wang N et al.
The Embo Journal, 2006
Regulation of large-scale chromatin unfolding by Smad4.
Yan J et al.
Biochemical and Biophysical Research Communications, 2004
Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C et al.
Oncogene, 2004
Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.
Imai Y et al.
Oncogene, 2001
Select a paper to view details